Adoptive Cell Therapy for Metastatic Melanoma
Authors:
- Orit ItzhakiOIOrit Itzhaki
- Gal MarkelGMGal Markel
- Jacob SchachterJSJacob Schachter
- Michal J. BesserMBMichal J. Besser
- 1 January 2017
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 23 (1) , 48-53
Abstract
Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TILs) is a powerful form of immunotherapy by inducing durable complete responses that significantly extend the survival of melanoma patients. Mutation-derived neoantigens were recently identified as key factors for tumor recognition and rejection by TILs. The isolation of T-cell receptor (TCR) genes directed against neoantigens and their retransduction into peripheral T cells may provide a new form of ACT.Genetic modifications of T cells with chimeric antigen receptors (CARs) have demonstrated remarkable clinical results in hematologic malignancies, but are so far less effective in solid tumors. Only very limited reports exist in melanoma. Progress in CAR T-cell engineering, including neutralization of inhibitory signals or additional safety switches, may open opportunities also in melanoma.We review clinical results and latest developments of adoptive therapies with TILs, T-cell receptor, and CAR-modified T cells and discuss future directions for the treatment of melanoma.Keywords
This publication has 56 references indexed in Scilit:
- Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 RegimenClinical Cancer Research, 2016
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic MelanomaJournal of Clinical Oncology, 2016
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with ResponseClinical Cancer Research, 2015
- Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior ImmunotherapiesClinical Cancer Research, 2013
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene TherapyJournal of Immunotherapy, 2013
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer TherapyJournal of Immunotherapy, 2011
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenBlood, 2009
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002